Table 6 Accelerated stability study
Time in months | Characterisation of F9 formulation | Characterisation of F14 formulation | ||||||
|---|---|---|---|---|---|---|---|---|
Drug content (%)* | Floating lag time (s)* | Floating duration (h)* | T95%* | Drug content (%)* | Floating lag time (h)* | Floating duration (h)* | T95% (h)* | |
0 | 98 ± 3.4 | 18 ± 1 | 14 ± 0.3 | 12 ± 0.4 | 98 ± 4.3 | 22 ± 1 | 14 ± 0.4 | 12 ± 0.6 |
1 | 97.5 ± 2.1 | 16 ± 0.5 | 13.5 ± 0.5 | 12 ± 0.2 | 97 ± 3.2 | 20 ± 0.7 | 11.5 ± 0.3 | 10.5 ± 0.5 |
3 | 97 ± 2.6 | 14 ± 0.6 | 13 ± 0.2 | 12 ± 0.1 | 96.5 ± 2.5 | 18 ± 0.5 | 10.5 ± 0.7 | 10 ± 0.3 |
6 | 97 ± 3.1 | 15 ± 1 | 13 ± 0.4 | 12 ± 0.2 | 96 ± 4.1 | 13 ± 0.6 | 9 ± 0.3 | 9.5 ± 0.4 |